Immunogenicity of anti-SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases
Immunogenicity of anti-SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases

Immunogenicity of anti-SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases

user4304645171849

20 min
News
Play

Description

In this podcast, we invite two authors from recent ARD papers dedicated to the efficacy of mRNA vaccines in patients with immunosuppressive therapies. Christophe Richez, Department of Rheumatology, University Medical Center, Bordeaux, France, and ARD's Social Media Advisor, interviews Bimba Hoyer, Department for Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Germany, and Rebecca H Haberman, Division of Rheumatology, University Grossman School of Medicine, New York, USA. They describe their works and offer their thoughts on the current situation in this area and the future. Related content: https://ard.bmj.com/content/early/2021/05/11/annrheumdis-2021-220272 https://ard.bmj.com/content/early/2021/06/07/annrheumdis-2021-220597

Uploader

jeff_clouds

jeff_clouds

Immunogenicity of anti-SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases - Listen Free | WowFM